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Abstract 
Purpose: To investigate the antidepressant effect of Cyperus rotundus L. extract (CRLE) in rats. 
Methods: A rat model of depression was prepared for behavioral tests including tail suspension test or 
forced swimming test. Wistar rats were randomly divided into six groups (n = 10): normal group (0.9 % 
NaCl), model group (0.9 % NaCl), positive drug group (fluoxetine 30 mg/kg) as well as CRLE groups, 
namely, 200, 400 and 800 mg/kg doses. All drugs were orally administered at 14: 00 - 15: 00 h for 1, 7 
and 14 days, respectively. Tail suspension and forced swimming tests were conducted 1 h after the last 
treatment. Monoamine oxidize A (MAO) assay was commenced in rats after 14-day administration. 
Except for the rats in normal group, other group participated in the behavioral tests. 
Results: The effect of 800 mg/kg CRLE was more potent than the positive drug fluoxetine. CRLE (≥ 
200 mg/kg) treatment for 14 days significantly inhibited brain MAO activity in rats (p < 0.01) in a dose-
dependent manner. Oral administration of 800 mg/kg CRLE produced MAO B inhibitory activity in rat 
brain (p < 0.01). Fluoxetine inhibited both brain MAO A and B activities in rats (p < 0.01).  
Conclusion: The results suggest that CRLE produces significant antidepressant effect in rats, and 
therefore, may be useful for the treatment of depressed patients, but further studies are required to 
ascertain this. 
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Depression is a major disease affecting nearly 13 
- 20 % of people in the world. [1]. In spite of the 
introduction of the tricyclic antidepressants 
(TCAs), selective reversible inhibitors of 
monoamine oxidize A (RIMAs), selective 
serotonin reuptake inhibitors (SSRIs) and 
specific serotonin-noradrenaline reuptake 
inhibitors (SNRIs), depression continues to be a 
major medical problem. However, search for new 
antidepressant drug continues. According to the 
theory of the Traditional Chinese Medicine 
(TCM), the clinical condition of depression could 
be mainly classified into liver qi stagnation, the 
symptom of which can be described as mental 
stress, hypochondriac distensive pain, or lumps 
in the breasts, hernia pain and irregular 
menstruation. Based on this, many Chinese 
medicinal plants were successfully used to 
manage the disorder of depression using the 
active principles of some plants [2,3]. 
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Cyperus rotundus L. is a well-known indigenous 
herbal medicine for treating depression in China. 
In this study, we examined the in vivo 
antidepressant activity of CRLE in rat models of 
immobility tests as well as MAO activity in rat 
whole brain in comparison with the effects of 




Plant material and extraction 
 
All the herbal samples of Cyperus rotundus L. 
were collected from Changsha City, Hunan 
Province in China in March 2016. Taxonomic 
identification of all the plants were performed by 
Professor Shan Li of Shandong University in 
China. A voucher specimen (no. CRLE 
20160306) was deposited in the herbarium of 
College of Pharmacy, Shandong University, 
China for future reference.  
 
The whole plant of Cyperus rotundus L. was 
dried in a drying oven at 100 oC for 12 h. CRLE 
was obtained by steeping the dried 
Cyperus rotundus L. in water at 60 oC three 
times, each for 1 h before first drying in an oven 
and then freeze-drying the last extract thus 
obtained. One gram powder was obtained from 




Wistar rats weighing 150 - 180 g were provided 
by the Experimental Animal Center of Shandong 
Province (certificate no. SYXK 2003-0007). The 
animals had free access to food and water, and 
were allowed to acclimatize for at least one week 
before use. The rat experiment was approved by 
the Animal Care and Use Committee of 
Shandong University (approval ref no. 20110403) 
and was carried out in compliance with Directive 
2010/63/EU on the Handling of Animals Used for 
Scientific Purposes [4]. 
 
Animal model and groups  
 
The rat model of depression was prepared by the 
behavioral tests including tail suspension test 
and forced swimming test. The rats were 
randomly divided into six groups of ten rats in 
each: normal group (0.9 % NaCl), model group 
(0.9 % NaCl), positive drug group (fluoxetine 30 
mg/kg) as well as CRLE groups, 200, 400 and 
800 mg/kg doses. All drugs were orally 
administered at 14: 00 - 15: 00 h for 1, 7 or 14 
days, respectively. The behavioral tests were 
conducted 1 h after the last treatment, 
respectively. MAO assay started in rats after 14-
day administration. Except for the rats in normal 
group, all other rats participated in the behavioral 
tests. 
 
Tail suspension test 
 
The tail suspension test was based on the 
method of Steru [5]. Rats was individually 
suspended by the tail with clamp (1 cm distant 
from the end) for 6 min in a box with the head 5 
cm to the bottom. The experiment was carried 
out in a darkened room with minimal background 
noise. The duration of immobility was observed 
during the final 4 min interval. 
 
Forced swimming test 
 
Rats were individually forced to swim for 6 min, 
in glass cylinders (20 cm in height; 14 cm in 
diameter), containing fresh water up to a height 
of 10 cm at 25 oC. After 6 min, they were 
removed and dried with a towel. They were again 
forced to swim in a similar environment for a 
period of 6 min 24 h later. The duration of 





The mitochondrial fraction suspended in 10 vol. 
of cold sodium phosphate buffer (10 mM, pH 7.4, 
containing 320 mM sucrose), was mixed at 4 oC 
for 20 min. The mixture was centrifuged at 15 
000×/g for 30 min at 0 oC and the pellets were re-
suspended in the same buffer. The protein 
concentration was adjusted to 1 mg/mL. Protein 
concentration was estimated by the Lowry 
method [6] using bovine serum albumin as the 
standard. MAO activity was assessed as 
described previously [7]. The assay mixtures 
contained 4 mM 5-HT or 2 mM b-PEA as specific 
substrates for MAO A and B, respectively, 250 
mL solution of the mitochondrial fraction, and 100 
mM sodium phosphate buffer (pH 7.4) up to a 
final volume of 1 mL. The reaction was allowed 
to proceed at 37 oC for 20 min, and stopped by 
adding 1 M HCl (200 mL), the reaction product 
was extracted with 5 ml of butyl acetate (for MAO 
A assay) or cyclohexane (for MAO B assay), 
respectively. The organic phase were measured 
at wavelength of 280 nm for MAO A assay and 
242 nm for MAO B assay with 
spectrophotometer, respectively. Blank samples 
were prepared by adding 1 M HCl (200 mL) prior 





Values are expressed as mean ± SD (n = 10). 
Significant differences between the groups were 
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analyzed using one-way analysis of variance 
(ANOVA) followed by two-paired Student’s t-test. 




Effect of CRLE on duration of immobility  
 
Rat tail suspension 
 
As shown in Table 1, CRLE reduced the 
immobility time after 7-day treatment. After a 14-
day treatment, CRLE at the doses of 200, 400 
and 800 mg/kg significantly decreased the 
duration of immobility in a dose-dependent 
manner, resulting in 31.7, 43.6 and 52.7 % 
immobility reduction, respectively (p < 0.05). 
However, the reference antidepressant fluoxetine 
at the dose of 30 mg/kg resulted in significant 
reduction (p < 0.05). CRLE at the doses of 400 
and 800 mg/kg appeared to be more potent than 
that of fluoxetine after 14-day treatment. 
 
Rat forced swimming  
 
As shown in Table 2, CRLE showed no change 
after 1 day treatment. CRLE at the dose of 800 
mg/kg exhibited to show significant immobility 
reduction after 7-day treatment. The extracts at 
doses of 200, 400 and 800 mg/kg significantly 
decreased the duration of immobility in a dose-
dependent manner, resulting in 49.8, 60.6 and 
65.4 % immobility reduction after 14-day 
treatment, respectively. Fluoxetine at the dose of 
30 mg/kg significantly produced a time-
dependent immobility reduction. CRLE at the 
dose of 800 mg/kg appeared to be more potent 
than that of fluoxetine after 14-day treatment. 
 
Effect of CRLE on MAO A and B activities in 
rat whole brain 
 
The effects of CRLE and fluoxetine for 14 days 
on the MAO A and B activities in rat whole brain 
was shown in Table 3. The MAO A and B 
activities in normal group were 31.6 ±/1.9  
 
Table 1: Effect of CRLE on the duration of immobility in the rat tail suspension test (mean ± SD, n = 10) 
 
Group Dose (mg/kg) Duration of immobility (s) 
  Day 1 Day 7 Day 14 Normal - 75.3±2.4 95.2±3.1 84.2±2.4 
Model 
Fluoxetine 
  -      
30 
 78.6±2.6       
80.1±1.8 
  65.6±2.4△       
 50.5±2.6** 
  40.5±3.2△△ 
 44.3±2.6** 
CRLE-H 800 77.5±3.5  66.4±3.1**  46.8±1.9** 
CRLE-M 400 76.3±2.7  68.7±2.2**  44.3±2.4** 
CRLE-L 200 77.9±3.1 59.4±2.1 37.2±3.1 
CRLE-H: High dose of CRLE; CRLE-M: Middle dose of CRLE; CRLE-L: Low dose of CRLE. △p < 0.05, △△p < 0.01 
when compared with normal groups, *p < 0.05, **p < 0.01 when compared with model groups 
 
Table 2: Effects of CRLE on the duration of immobility in the rat forced swimming test (mean ± SD, n = 10) 
 
Group Dose (mg/kg) Duration of immobility (s) 
  Day 1 Day 7 Day 14 Normal - 84.2±2.1 56.4±2.7 37.4±3.1 
Model              
Fluoxetine 
-          
30 
  83.5±1.7       
86.1±1.8 
  79.3±2.3△△      
70.6±2.5* 
  50.2±2.9△△ 
37.6±1.6** 
CRLE-H 800 79.4±2.3 58.6±2.4* 36.8±1.4** 
CRLE-M 400 75.3±3.4 69.3±2.3 38.3±1.5** 
CRLE-L 200 77.6±2.6 72.2±1.8 46.4±2.4* 
CRLE-H: High dose of CRLE; CRLE-M: Middle dose of CRLE; CRLE-L: Low dose of CRLE; △p < 0.05, △△p < 0.01 
when compared with normal groups, *p < 0.05, **p < 0.01 when compared with model groups 
 
Table 3: Effect of CRLE on MAO activity in rat whole brain (mean ± SD, n = 10) 
 
Group Dose (mg/kg) MAO activity (nmol/mg protein h) MAO inhibition (%) 
  A B A    B Normal - 31.6±1.9 25.8±1.5 - - 
Model        
Fluoxetine 










CRLE-H 800 17.2±1.5** 18.6±1.7** 44.7 37.3 
CRLE-M 400 13.6±1.7* 15.9±1.7* 33.4 17.6 
CRLE-L 200 10.5±1.6 14.2±1.5 24.2 8.5 
CRLE-H: high dose of CRLE; CRLE-M: medium dose of CRLE; CRLE-L: low dose of CRLE. △p < 0.05, △△p < 0.01 
when compared with normal groups, *p < 0.05, **p < 0.01 when compared with model groups 
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nmol/mg protein h and 25.8 ±1.5 nmol/mg protein 
h, respectively. Oral administration of the extract 
at doses of 200, 400 and 800 mg/kg significantly 
inhibited MAO A activity in a dose-dependent 
manner, providing 23.3, 32.6 and 45.2 % 
inhibition. However, only CRLE at a dose of 800 
mg/kg significantly inhibited MAO B activity, 
producing 37.3 % inhibition. Fluoxetine at the 
dose of 30 mg/kg also reduced the MAO A and B 




The tail suspension and forced swimming tests 
are two behavioral tests in rodent that predicted 
the clinical efficacy of many types of 
antidepressant treatments [8-10]. CRLE at oral 
doses from 200 to 800 mg/kg for 14 days 
significantly decreased the duration of immobility 
in the tail suspension test and the forced 
swimming test in rats. These behavioral effects 
of CRLE at the dose of 800 mg/kg were more 
potent than that of fluoxetine after 14-day 
treatment. As changes in immobility may be due 
to changes in locomotor activity caused by 
central nervous system stimulating agents, rats 
were tested in the open field test. These data in 
the present study showed that CRLE has 
antidepressant effects in rat models of immobility 
tests. 
 
MAO is an important enzyme in the metabolism 
of a wide range of monoamine neurotransmitters, 
including noradrenaline, dopamine, and 5-
hydroxytryptamine [11-13]. MAO exists in two 
forms, A and B. MAO A is more important than 
MAO B in the metabolism of the major 
neurotransmitter monoamines. MAO A inhibitors 
have been regarded as drugs for treating 
depression in clinical [14-16]. In the present 
investigation, we have demonstrated that the 
CRLE significantly inhibited in vivo MAO A 
activity in rat whole brain in a dose-dependent 
manner. However, only CRLE at a dose up to 
800 mg/kg exhibited to have the MAO B 
inhibitory activity. These findings suggest that 
anti-depressant effects of CRLE in rat models of 
immobility tests may be related to the inhibitory 




The findings of this study suggest that CRLE 
exhibits significant antidepressant effect in rats, 
and therefore can be potentially developed for 
clinical application for the treatment of 
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